FDA Issues New Guidance on Current Good Manufacturing Practices for Drugs - Arnold & Porter
FDA has issued new guidance on Current Good Manufacturing Practices (cGMP) for drugs, impacting compliance requirements for manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers, including branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate review and implementation as per operational timelines.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New guidance on cGMP that may affect manufacturing processes and compliance protocols.
Who it affects
All pharmaceutical manufacturers, including branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B).
What you must do
Review and update manufacturing practices to align with the new cGMP guidance.
Deadline
Immediate review and implementation as per operational timelines.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Issuance of Priority Review Voucher; Rare Pediatric Disease Product; GENGLYCOS (parisglasgene brecaparvovec-opnr)
- Determination That CARAFATE (Sucralfate) Oral Suspension, 1 Gram/10 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- UW Carbone Cancer Center receives FDA clearance to test new regenerative medicine therapy for radiotherapy-induced dry mouth - med.wisc.edu
- GLP-1 Drugs: Ohio Board of Pharmacy Issues FAQs for Compounders - natlawreview.com
- Missouri challenges FDA approval of new generic mifepristone in push to limit abortion - missouriindependent.com